Madrigal Pharmaceuticals Inc
Most Recent
Madrigal Pharmaceuticals Is Advancing Its NASH Pipeline in 2018
Madrigal Pharmaceuticals (MDGL) is currently trading at price-to-book and price-to-cash-flow ratios of 5.6x and 5.81x, respectively.
Madrigal Pharmaceuticals Stock in the First Half of October
Madrigal Pharmaceuticals’ (MDGL) stock price has dropped by 10.87% from $212.26 on October 1 to $189.18 on October 15.
A Look at Intercept Pharmaceuticals’ Exciting Research Pipeline
In this series, we’ll analyze three pharmaceutical companies with focused nonalcoholic steatohepatitis pipelines.
Intercept Pharmaceuticals’ Stock Price Rose 17.94% on August 6
On August 6, Intercept Pharmaceuticals’ (ICPT) stock price grew ~17.94% to $114.71—compared to the previous day’s closing price of $97.26.
Galmed Stock Rose Over 26% on ‘Overweight’ Rating
Today, Galmed Pharmaceuticals (GLMD) soared as Cantor Fitzgerald initiated coverage on the stock with an “overweight” rating and a target price of $59.
What’s behind Gemphire Therapeutics’ Stock Price Rise
On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7.
Analysts Are Bullish on Viking Therapeutics Stock
On June 1, Viking Therapeutic had a consensus 12-month target price of $10.63, which implies a 12-month investment return potential of ~4.7%.
Viking Therapeutics Stock Rose 101% on May 31
On May 31, Viking Therapeutics (VKTX) closed at $9.99—a rise of ~101% from the previous day’s closing price of $4.97.